Processa Pharmaceuticals Inc
For the period ended May 12, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 12, 2025 · Filed May 12, 2025
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Materials Pursuant to §240.14a-12 |
Processa Pharmaceuticals, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
| Payment of Filing Fee (Check the appropriate box): | |
|---|---|
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Rules 14a-6(i)(1) and 0-11. |
Hanover, MD 21076
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 30, 2025
To the Stockholders of Processa Pharmaceuticals, Inc.:
NOTICE HEREBY IS GIVEN that the 2025 Annual Meeting of Stockholders of Processa Pharmaceuticals, Inc. will be held at our corporate office located at 7380 Coca Cola Drive, Suite 106, Hanover, MD 21076 on Monday, June 30, 2025, beginning at 1:00 p.m., Eastern Time. The Annual Meeting will be held for the following purposes:
| 1. | To elect the six directors nominated in the attached Proxy Statement to serve as directors until the 2026 Annual Meeting of Stockholders and until their respective successors have been elected and qualified; |
| 2. | To approve the issuance of shares of common stock upon exercise of the Series A and B Warrants sold pursuant to the Securities Purchase Agreements entered into on January 27, 2025 in accordance with Nasdaq listing rules; |
| 3. | To ratify the appointment of Cherry Bekaert, LLP as the independent registered public accounting firm of Processa Pharmaceuticals, Inc. for the fiscal year ending December 31, 2025; |
| 4. | To approve, by advisory vote, the compensation of our 2025 named executive officers; and |
| 5. | To transact such other business as properly may come before the Annual Meeting or any adjournments or postponements thereof. |
The Board of Directors is not aware of any other business to be presented to a vote of the stockholders at the Annual Meeting. Information relating to the above matters is set forth in the attached Proxy Statement.
The Board of Directors has fixed the close of business on May 1, 2025 as the record date for the determination of stockholders entitled to receive notice of and to vote at the Annual Meeting or any adjournment thereof. Stockholders who own shares of the Company’s common stock beneficially through a bank, broker or other nominee will also be entitled to attend the Annual Meeting. The Annual Meeting may be adjourned from time to time without notice other than announcement at the Annual Meeting, and any business for which notice of the Annual Meeting is hereby given may be transacted at any such adjournment. A list of the stockholders entitled to vote at the Annual Meeting will be open to examination by any stockholder entitled to vote at the Annual Meeting, for any purpose germane to the Annual Meeting, during ordinary business hours and upon appointment, for a period of at least ten days prior to the Annual Meeting at the principal executive offices of the Company in Hanover, Maryland.
Your vote is very important to us, and it is important to us that your shares are represented regardless of the number of shares you may vote. We hope you will be able to attend the Annual Meeting, but in any event, we would appreciate you submitting your proxy as promptly as possible. You may vote by telephone or the Internet as instructed in the Notice of Internet Availability of Proxy Materials and in the accompanying proxy. If you received a copy of the Proxy Card by mail, you may also submit your vote by mail. We encourage you to vote by telephone or the Internet. These methods are convenient and save the Company significant postage and processing charges. If you attend the Annual Meeting, you may revoke your proxy and vote in person.
By order of the Board of Directors
/s/ George Ng
Chief Executive Officer
Hanover, Maryland
May 12, 2025
i
Table of Contents
| Proxy Statement Summary | 2 |
|---|---|
| Proposals to be Voted on at the 2025 Annual Meeting | |
| Proposal No. 1: Election of Directors | 6 |
| Proposal No. 2: Approval of Issuance of Shares Upon Exercise of Series A and B Warrants | 8 |
| Proposal No. 3: Ratification of the Appointment of the Independent Registered Public Accounting Firm Audit Committee Report | 9 |
| Proposal No. 4: Advisory Approval of Named Executive Officer Compensation | 11 |
| Corporate Governance Matters | 12 |
| Executive Officers of the Company | 15 |
| Executive Compensation | 16 |
| Pay Versus Performance | 23 |
| Director Compensation | 25 |
| Security Ownership of Certain Beneficial Owners and Management | 27 |
| Stockholder Proposals | 29 |
| Stockholder Communications with the Board of Directors | 29 |
| Other Matters | 29 |
Cautionary Note Regarding Forward-Looking Statements
The statements included in this Proxy Statement regarding future performance and results, expectations, plans, strategies, priorities, commitments, and other statements that are not historical facts are forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking, and other statements in this Proxy Statement regarding our environmental and other sustainability plans and goals, are not an indication that these statements are necessarily material to investors or are required to be disclosed in our filings with the SEC. In addition, historical, current, and forward-looking statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. Forward-looking statements are based upon current beliefs, expectations, and assumptions and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual results to differ materially from the forward-looking statements. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. Readers of this Proxy Statement are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Hanover, MD 21076
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.